| Dennis Joseph Mcdonagh, MD | |
|
425 N Lee St, Ste 101, Jacksonville, FL 32257 | |
| (904) 549-8228 | |
| (904) 549-8230 |
| Full Name | Dennis Joseph Mcdonagh |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Pulmonary Disease |
| Location | 425 N Lee St, Jacksonville, Florida |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073623153 | NPI | - | NPPES |
| 08658 | Other | FL | WELLCARE MEDICARE |
| 15688 | Other | FL | BLUE CROSS BLUE SHIELD |
| 210079 | Other | FL | AVMED |
| 5082045 | Other | FL | AETNA |
| 1870729005 | Other | FL | CIGNA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | ME0039836 (Florida) | Primary |
| Entity Name | Eugene H Mccoskey Do Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750733580 PECOS PAC ID: 2961781984 Enrollment ID: O20161115002564 |
News Archive
InterMune, Inc. today announced the pricing of its underwritten public offering of 7,000,000 shares of newly issued common stock at a price to the public of $14.10 per share.
Stemedica Cell Technologies, Inc. (Stemedica), a world leader in stem cell research and manufacturing, announced that it has filed an Investigative New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for a clinical trial. The trial will assess the safety, tolerability and efficacy of Stemedica's high potency proprietary allogeneic mesenchymal bone marrow-derived stem cells (adult human) as a treatment for ischemic stroke.
Kessler Foundation researchers found that processing speed is the primary limiting factor associated with activity and participation in everyday life among people with multiple sclerosis (MS). "Factors that moderate activity limitation and participation restriction in people with multiple sclerosis" was published in the American Journal of Occupational Therapy.
The full characterization of biotherapeutics is required by regulatory authorities as properties such as safety, efficacy and the serum half-life of therapeutic proteins can be affected by differences in their glycosylation pattern. Recombinant monoclonal antibody therapeutics (mAbs) represent the largest group of therapeutic proteins the analysis of the glycan pattern is therefore an essential part of the mAb characterization process.
Doctors at the North Shore-LIJ Health System on Saturday will present late-breaking data showing that an investigational drug Triferic is well tolerated and effective in treating iron deficiency in patients with chronic kidney disease undergoing dialysis.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dennis Joseph Mcdonagh, MD 2636 Forest Circle, Jacksonville, FL 32257 Ph: (904) 549-8228 | Dennis Joseph Mcdonagh, MD 425 N Lee St, Ste 101, Jacksonville, FL 32257 Ph: (904) 549-8228 |
News Archive
InterMune, Inc. today announced the pricing of its underwritten public offering of 7,000,000 shares of newly issued common stock at a price to the public of $14.10 per share.
Stemedica Cell Technologies, Inc. (Stemedica), a world leader in stem cell research and manufacturing, announced that it has filed an Investigative New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for a clinical trial. The trial will assess the safety, tolerability and efficacy of Stemedica's high potency proprietary allogeneic mesenchymal bone marrow-derived stem cells (adult human) as a treatment for ischemic stroke.
Kessler Foundation researchers found that processing speed is the primary limiting factor associated with activity and participation in everyday life among people with multiple sclerosis (MS). "Factors that moderate activity limitation and participation restriction in people with multiple sclerosis" was published in the American Journal of Occupational Therapy.
The full characterization of biotherapeutics is required by regulatory authorities as properties such as safety, efficacy and the serum half-life of therapeutic proteins can be affected by differences in their glycosylation pattern. Recombinant monoclonal antibody therapeutics (mAbs) represent the largest group of therapeutic proteins the analysis of the glycan pattern is therefore an essential part of the mAb characterization process.
Doctors at the North Shore-LIJ Health System on Saturday will present late-breaking data showing that an investigational drug Triferic is well tolerated and effective in treating iron deficiency in patients with chronic kidney disease undergoing dialysis.
› Verified 1 days ago
Dr. Jami Ann Rothe Kinnucan, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 4500 San Pablo Rd S, Jacksonville, FL 32224 Phone: 904-953-2000 | |
Michelle Tulang, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 4500 San Pablo Rd S, Jacksonville, FL 32224 Phone: 904-953-2000 | |
Dr. Minnsun Koh Park, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3900 University Blvd S, Jacksonville, FL 32216 Phone: 904-222-6656 | |
Sandrela Mussallam Abu Shaibeh, Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 820 Prudential Dr Ste 304, Jacksonville, FL 32207 Phone: 904-202-3860 Fax: 904-202-3846 | |
Krunal Patel, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 4800 Belfort Rd, Jacksonville, FL 32256 Phone: 904-398-7205 Fax: 904-396-4047 | |
Zaid Abdel Rahman, M.D. Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 4500 San Pablo Rd S, Jacksonville, FL 32224 Phone: 904-953-2000 | |
Sina O'sullivan, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 4500 San Pablo Rd S, Jacksonville, FL 32224 Phone: 904-953-2000 |